Trial in Process: Phase 1 studies of BI 1701963, a SOS1::KRAS Inhibitor, in combination with MEK inhibitors, irreversible KRASG12C inhibitors or irinotecan

被引：0
|
作者：
Hofmann, Marco H. [1 ]
Lu, Hengyu [2 ]
Duenzinger, Ulrich [3 ]
Gerlach, Daniel [1 ]
Trapani, Francesca [1 ]
Machado, Annette A. [2 ]
Daniele, Joseph R. [2 ]
Waizenegger, Irene [1 ]
Gmachl, Michael [1 ]
Rudolph, Dorothea [1 ]
Vellano, Christopher P. [2 ]
Marotti, Marcelo [3 ]
Vucenovic, Vitomir [3 ]
Heffernan, Timothy P. [2 ]
Marszalek, Joseph R. [2 ]
Petronczki, Mark P. [1 ]
Kraut, Norbert [1 ]
机构：
[1] Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[3] Boehringer Ingelheim Int GmbH, Ingelheim, Germany
来源：
CANCER RESEARCH | 2021年 / 81卷 / 13期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT210
引用
收藏
页数：2
相关论文
共 50 条
  • [1] BI-3406 and BI 1701963: Potent and selective SOS1::KRAS inhibitors induce regressions in combination with MEK inhibitors or irinotecan
    Gerlach, Daniel
    Gmachl, Michael
    Ramharter, Juergen
    Teh, Jessica
    Fu, Szu-Chin
    Trapani, Francesca
    Kessler, Dirk
    Rumpel, Klaus
    Botesteanu, Dana-Adriana
    Ettmayer, Peter
    Arnhof, Heribert
    Gerstberger, Thomas
    Kofink, Christiane
    Wunberg, Tobias
    Vellano, Christopher P.
    Heffernan, Timothy P.
    Marszalek, Joseph R.
    Pearson, Mark
    McConnell, Darryl B.
    Kraut, Norbert
    Hofmann, Marco H.
    CANCER RESEARCH, 2020, 80 (16)
  • [2] Trial in progress: Phase 1 study of BI 1823911, an irreversible KRASG12C inhibitor targeting KRAS in its GDP-loaded state, as monotherapy and in combination with the pan-KRAS SOS1 inhibitor BI 1701963 in solid tumors expressing KRASG12C mutation
    Waizenegger, Irene C.
    Lu, Hengyu
    Thamer, Claus
    Savarese, Fabio
    Gerlach, Daniel
    Rudolph, Dorothea
    Vellano, Christopher P.
    Marotti, Marcelo
    Heymach, John
    Kopetz, Scott
    Heffernan, Timothy P.
    Marszalek, Joseph R.
    Petronczki, Mark P.
    Hofmann, Marco H.
    Kraut, Norbert
    CANCER RESEARCH, 2022, 82 (12)
  • [3] Probing and overcoming KRASG12C inhibitor resistance by combination with a pan-KRAS SOS1 inhibitor
    Hofmann, Marco H.
    Jurado, Sabine
    Gerlach, Daniel
    Koga, Takamasa
    Trapani, Francesca
    Gmachl, Michael
    Alpar, Donat
    Lieb, Simone
    Jeschko, Astrid
    Mitsudomi, Tetsuya
    Kraut, Norbert
    Petronczki, Mark P.
    CANCER RESEARCH, 2022, 82 (12)
  • [4] A Potent SOS1 PROTAC Degrader with Synergistic Efficacy in Combination with KRASG12C Inhibitor
    Lv, Yan
    Yang, Zixuan
    Chen, Yiming
    Ma, Xuepei
    Guo, Mengqi
    Zhang, Chengwei
    Jiang, Xiaolin
    Wang, Chengli
    Li, Zhuoyue
    Tai, Zhengfu
    Wang, Xiao
    Zhang, Siqi
    Ma, Shumin
    Qin, Chong
    JOURNAL OF MEDICINAL CHEMISTRY, 2024, 67 (04) : 2487 - 2511
  • [5] SOS1 Inhibition Enhances the Efficacy of KRASG12C Inhibitors and Delays Resistance in Lung Adenocarcinoma
    Daley, Brianna R.
    Sealover, Nancy E.
    Finniff, Bridget A.
    Hughes, Jacob M.
    Sheffels, Erin
    Gerlach, Daniel
    Hofmann, Marco H.
    Kostyrko, Kaja
    Lamorte, Joseph P.
    Linke, Amanda J.
    Beckley, Zaria
    Frank, Andrew M.
    Lewis, Robert E.
    Wilkerson, Matthew D.
    Dalgard, Clifton L.
    Kortum, Robert L.
    CANCER RESEARCH, 2025, 85 (01) : 118 - 133
  • [6] Co-targeting SOS1 enhances the antitumor effects of KRASG12C inhibitors by addressing intrinsic and acquired resistance
    Thatikonda, Venu
    Lyu, Hengyu
    Jurado, Sabine
    Kostyrko, Kaja
    Bristow, Christopher A.
    Albrecht, Christoph
    Alpar, Donat
    Arnhof, Heribert
    Bergner, Oliver
    Bosch, Karin
    Feng, Ningping
    Gao, Sisi
    Gerlach, Daniel
    Gmachl, Michael
    Hinkel, Melanie
    Lieb, Simone
    Jeschko, Astrid
    Machado, Annette A.
    Madensky, Thomas
    Marszalek, Ethan D.
    Mahendra, Mikhila
    Melo-Zainzinger, Gabriella
    Molkentine, Jessica M.
    Jaeger, Philipp A.
    Peng, David H.
    Schenk, Robyn L.
    Sorokin, Alexey
    Strauss, Sandra
    Trapani, Francesca
    Kopetz, Scott
    Vellano, Christopher P.
    Petronczki, Mark
    Kraut, Norbert
    Heffernan, Timothy P.
    Marszalek, Joseph R.
    Pearson, Mark
    Waizenegger, Irene C.
    Hofmann, Marco H.
    NATURE CANCER, 2024, 5 (09) : 1352 - 1370
  • [7] Combination of KRASG12C and FGFR1 inhibitors as a resistance-overcoming therapeutic strategy for maximizing therapeutic impact of KRASG12C inhibitors
    Santos, Alba
    Plaza, Patricia
    Jimenez, Marta
    Gomez-Sanchez, David
    Paz-Ares, Luis
    Ferrer, Irene
    CANCER RESEARCH, 2024, 84 (06)
  • [8] Combination of SOS1::KRAS inhibitor with a MEK inhibitor reconfigures the immune tumor microenvironment of KRASG12D pancreatic ductal adenocarcinomas and sensitizes to immunotherapy
    Norgard, Robert J.
    Budhani, Pratha
    O'Brian, Sarah
    Potts, Jessica
    Flynn, Brianna
    Salce, Xavier
    Tagore, Joshua
    Thiede, Lucinda
    Seco, Joseph
    Segal, Suzanne
    Love, Mark
    Mikucka, Ania
    Cote, Charlie
    Wasti, Ruby
    Kamalakannan, Mohanapriya
    Jeschko, Astrid
    Melo-Zainzinger, Gabriela
    Mcnabola, Angela
    DiBlasi, Varenka Rodriguez Rodriguez
    Tumang, Joseph
    Tontsch-Grunt, Ulrike
    Hinkel, Melanie
    Pignatelli, Jeanine
    Trapani, Francesca
    Martinez-Morilla, Sandra
    Kostyrko, Kaja
    Hofmann, Marco H.
    Kashyap, Abhishek
    Flano, Emilio
    Liu, Kang
    CANCER IMMUNOLOGY RESEARCH, 2022, 10 (12)
  • [9] Signature-driven repurposing of Midostaurin for combination with MEK1/2 and KRASG12C inhibitors in lung cancer
    Macaya, Irati
    Roman, Marta
    Welch, Connor
    Entrialgo-Cadierno, Rodrigo
    Salmon, Marina
    Santos, Alba
    Feliu, Iker
    Kovalski, Joanna
    Lopez, Ines
    Rodriguez-Remirez, Maria
    Palomino-Echeverria, Sara
    Lonfgren, Shane M.
    Ferrero, Macarena
    Calabuig, Silvia
    Ludwig, Iziar A.
    Lara-Astiaso, David
    Jantus-Lewintre, Eloisa
    Guruceaga, Elizabeth
    Narayanan, Shruthi
    Ponz-Sarvise, Mariano
    Pineda-Lucena, Antonio
    Lecanda, Fernando
    Ruggero, Davide
    Khatri, Purvesh
    Santamaria, Enrique
    Fernandez-Irigoyen, Joaquin
    Ferrer, Irene
    Paz-Ares, Luis
    Drosten, Matthias
    Barbacid, Mariano
    Gil-Bazo, Ignacio
    Vicent, Silve
    NATURE COMMUNICATIONS, 2023, 14 (01)
  • [10] Signature-driven repurposing of Midostaurin for combination with MEK1/2 and KRASG12C inhibitors in lung cancer
    Irati Macaya
    Marta Roman
    Connor Welch
    Rodrigo Entrialgo-Cadierno
    Marina Salmon
    Alba Santos
    Iker Feliu
    Joanna Kovalski
    Ines Lopez
    Maria Rodriguez-Remirez
    Sara Palomino-Echeverria
    Shane M. Lonfgren
    Macarena Ferrero
    Silvia Calabuig
    Iziar A. Ludwig
    David Lara-Astiaso
    Eloisa Jantus-Lewintre
    Elizabeth Guruceaga
    Shruthi Narayanan
    Mariano Ponz-Sarvise
    Antonio Pineda-Lucena
    Fernando Lecanda
    Davide Ruggero
    Purvesh Khatri
    Enrique Santamaria
    Joaquin Fernandez-Irigoyen
    Irene Ferrer
    Luis Paz-Ares
    Matthias Drosten
    Mariano Barbacid
    Ignacio Gil-Bazo
    Silve Vicent
    Nature Communications, 14
12345